Platform Technology
TRIDENT™: A Platform for
Cytosolic Delivery
A delivery platform designed to move therapeutic payloads beyond endosomal entrapment and into the cytosol, where intracellular targets can be engaged and biological activity can occur.
SCROLL
The Delivery Challenge
Endosomal Entrapment Limits Therapeutic Activity
After cellular uptake, many therapeutics remain trapped in endosomal compartments, preventing access to intracellular targets and degradation machinery. As a result, systemic exposure does not reliably translate into biological effect.
Confined in Endosomes
Internalized payloads may enter cells but remain sequestered away from their site of action.
Exposure Without Activity
Systemic drug levels can be present without meaningful target engagement or functional response.
Designed for Functional Cytosolic Delivery
TRIDENT™ is engineered to improve intracellular trafficking and enable cytosolic delivery, allowing payloads to reach the site of action inside the cell.
Improved Cellular Uptake
Enhances intracellular accumulation versus free payload.
Endosomal Escape
Supports release from endosomal compartments to enable cytosolic delivery.
Functional Target Engagement
Designed to translate delivery into measurable target engagement, degradation, and downstream pathway effects.
Mechanism of Action
How TRIDENT Delivers Inside the Cell
Following tumor accumulation and cellular uptake, TRIDENT™ is designed to overcome endosomal entrapment and release its payload into the cytosol. Cleavable linker chemistry then supports intracellular payload release at the site of action.
Why It Matters
Translational Impact
By addressing the gap between exposure and activity, TRIDENT™ is designed to improve the translational value of oncology programs across multiple modalities.
Increased Intracellular Exposure
More therapeutic reaches its intracellular site of action.
Improved Target
Engagement
Greater cytosolic delivery supports stronger and more consistent biological activity.
Potential to Expand Therapeutic Window
More selective delivery may widen the margin between efficacy and toxicity.
Asset Rescue
Potential
Programs limited by delivery rather than biology may be enabled through improved cytosolic delivery.
Platform Flexibility
Broad Modality Compatibility
TRIDENT™ is being evaluated across small molecules, protein degraders, biologics, and nucleic acid therapeutics where intracellular delivery remains a critical constraint.
Targeted Protein Degradation
PROTACs, molecular glues, and next-generation degraders all depend on cytosolic access. TRIDENT™ is specifically being evaluated for this modality as a primary focus.
Biologics (e.g., Nanobodies, Antibodies, ADCs/NDCs)
Nanobodies and antibodies depend on receptors for uptake and are often sequestered in endosomes or lysosomes, limiting cytosolic access. TRIDENT™ enables receptor-independent cytosolic delivery, allowing ADC- and NDC-format therapeutics to efficiently reach the cytosol, overcome low receptor expression, expand patient eligibility, and enhance efficacy.
Nucleic Acid Therapeutics
RNAi and ASO programs require cytosolic or nuclear access. TRIDENT™'s pH-responsive mechanism addresses the endosomal barrier common to nucleic acid delivery.
Targeted Chemotherapy
Tumor-selective delivery of cytotoxic payloads demonstrates the platform mechanism with validated preclinical data across uptake, escape, and functional activity.
Platform Impact
One Platform. A Multiplier Effect.
Our vision is to make functional intracellular delivery a solved problem — enabling entire classes of oncology therapies to reach their full clinical potential.